Skip to main content
Top
Published in: International Journal of Hematology 4/2024

09-02-2024 | Edoxaban | Original Article

Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants

Authors: Osamu Kumano, Shinya Suzuki, Masako Yamazaki, Yoshimori An, Masahiro Yasaka, Masahiro Ieko, For the Japanese Study Group for the Assessment of Direct Oral Anticoagulants

Published in: International Journal of Hematology | Issue 4/2024

Login to get access

Abstract

Age is a significant risk factor for ischemic stroke. However, the influence of aging on coagulation parameters in non-valvular atrial fibrillation (NVAF) patients treated with direct oral anticoagulants (DOACs) remains unclear. A total of 775 samples were collected from 224 NVAF patients receiving apixaban, edoxaban or rivaroxaban. The samples were categorized into three age groups: (i) ≤ 64 years, (ii) 65–74 years, and (iii) ≥ 75 years (apixaban: N = 48, 108, 119; edoxaban: N = 63, 68, 126; rivaroxaban: N = 115, 90, 38, respectively). Coagulation parameters including fibrinogen (Fbg), factor II, factor V, factor VII, factor X, and D-dimer, were compared between the three age groups for each drug. The slopes in the correlation between drug concentrations and modified diluted prothrombin time (mdPT) were also assessed. Fbg and factor V increased with age, while factor II and factor X decreased. Factor VII and D-dimer showed no significant differences across age categories. The slope in response to drug concentrations was similar between the age groups. In NVAF patients treated with apixaban, edoxaban and rivaroxaban, some coagulation parameters exhibited age-related variation. However, the response of mdPT to drug concentration was consistent across age categories.
Literature
1.
go back to reference Kario K, Matsuo T. High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system. J Cardiovasc Risk. 1994;1:165–71.CrossRefPubMed Kario K, Matsuo T. High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system. J Cardiovasc Risk. 1994;1:165–71.CrossRefPubMed
2.
go back to reference Tracy RP, Bovill EG, Fried LP, Heiss G, Lee MH, Polak JF, et al. High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system. Ann Epidemiol. 1992;2:509–19.CrossRefPubMed Tracy RP, Bovill EG, Fried LP, Heiss G, Lee MH, Polak JF, et al. High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system. Ann Epidemiol. 1992;2:509–19.CrossRefPubMed
3.
go back to reference Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, et al. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Am J Epidemiol. 1996;143:665–76.CrossRefPubMed Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, et al. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Am J Epidemiol. 1996;143:665–76.CrossRefPubMed
4.
go back to reference Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA, Rosenberg RD. Hypercoagulability in centenarians: the paradox of successful aging. Blood. 1995;85:3144–9.CrossRefPubMed Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA, Rosenberg RD. Hypercoagulability in centenarians: the paradox of successful aging. Blood. 1995;85:3144–9.CrossRefPubMed
5.
go back to reference Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMed Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMed
6.
go back to reference Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, ARISTOTLE Committees and Investigators, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefPubMed Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, ARISTOTLE Committees and Investigators, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefPubMed
7.
go back to reference Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510.CrossRefPubMed Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510.CrossRefPubMed
8.
go back to reference Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, ENGAGE AF-TIMI 48 Investigators, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefPubMed Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, ENGAGE AF-TIMI 48 Investigators, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefPubMed
9.
go back to reference Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756–60.CrossRef Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756–60.CrossRef
10.
go back to reference Gosselin RC, Adcock DM, Douxfils J. An update on laboratory assessment for direct oral anticoagulants (DOACs). Int J Lab Hematol. 2019;41(Suppl 1):33–9.CrossRefPubMed Gosselin RC, Adcock DM, Douxfils J. An update on laboratory assessment for direct oral anticoagulants (DOACs). Int J Lab Hematol. 2019;41(Suppl 1):33–9.CrossRefPubMed
11.
go back to reference Kumano O, Suzuki S, Yamazaki M, An Y, Yasaka M, Ieko M. Newly developed modified diluted prothrombin time reagent: a multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy. Thromb Res. 2022;210:87–90.CrossRefPubMed Kumano O, Suzuki S, Yamazaki M, An Y, Yasaka M, Ieko M. Newly developed modified diluted prothrombin time reagent: a multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy. Thromb Res. 2022;210:87–90.CrossRefPubMed
12.
go back to reference Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.CrossRefPubMed Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.CrossRefPubMed
13.
go back to reference Lip GYP, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMed Lip GYP, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMed
14.
go back to reference Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.CrossRefPubMed Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.CrossRefPubMed
15.
go back to reference Ieko M, Komiyama Y, Yamazaki S, Katagiri H, Shimazu C, Naito S, Matsuda M, Yuki Y, Miyata K, Arai R, Kumano O, Emmi M, Yoshida T, Tanaka H, Okuhara T, Yamashita T, Sekine Y, Homma M, Kawai Y, Tohyama K. Int J Hematol. 2020;112:614–20.CrossRefPubMed Ieko M, Komiyama Y, Yamazaki S, Katagiri H, Shimazu C, Naito S, Matsuda M, Yuki Y, Miyata K, Arai R, Kumano O, Emmi M, Yoshida T, Tanaka H, Okuhara T, Yamashita T, Sekine Y, Homma M, Kawai Y, Tohyama K. Int J Hematol. 2020;112:614–20.CrossRefPubMed
16.
go back to reference Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost. 2013;109:127–36.CrossRefPubMed Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost. 2013;109:127–36.CrossRefPubMed
17.
go back to reference Castellone DD, Castillo R, Depasse F, Doyle M, Halim AB, Kitchen S et al. Determination of coagulation factor activities using the one-stage clotting assay, in: Approved Guideline, 2nd edition, Clinical and Laboratory Standards Institute, Wayne, PA, 2016. CLSI Document H48-A. Castellone DD, Castillo R, Depasse F, Doyle M, Halim AB, Kitchen S et al. Determination of coagulation factor activities using the one-stage clotting assay, in: Approved Guideline, 2nd edition, Clinical and Laboratory Standards Institute, Wayne, PA, 2016. CLSI Document H48-A.
18.
go back to reference Ieko M, Ohmura K, Naito S, Yoshida M, Sakuma I, Ikeda K, et al. Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: results of multicenter study in Japan. Thromb Res. 2020;195:158–64.CrossRefPubMed Ieko M, Ohmura K, Naito S, Yoshida M, Sakuma I, Ikeda K, et al. Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: results of multicenter study in Japan. Thromb Res. 2020;195:158–64.CrossRefPubMed
19.
go back to reference Kario K, Matsuo T, Kobayashi H, Kanai N, Hoshide S, Mitsuhashi T, et al. Endothelial cell damage and angiotensin-converting enzyme insertion/deletion genotype in elderly hypertensive patients. J Am Coll Cardiol. 1998;32:444–50.CrossRefPubMed Kario K, Matsuo T, Kobayashi H, Kanai N, Hoshide S, Mitsuhashi T, et al. Endothelial cell damage and angiotensin-converting enzyme insertion/deletion genotype in elderly hypertensive patients. J Am Coll Cardiol. 1998;32:444–50.CrossRefPubMed
20.
go back to reference Ariyo AA, Tracy CTR. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108–15.CrossRefPubMed Ariyo AA, Tracy CTR. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108–15.CrossRefPubMed
21.
go back to reference Wong PC, Crain EJ, Xin B, Wexler RR, Lam PYS, Pinto DJ, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820–9.CrossRefPubMed Wong PC, Crain EJ, Xin B, Wexler RR, Lam PYS, Pinto DJ, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820–9.CrossRefPubMed
22.
go back to reference Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6:1542–9.CrossRefPubMed Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6:1542–9.CrossRefPubMed
23.
go back to reference Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K-H, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514–21.CrossRefPubMed Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K-H, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514–21.CrossRefPubMed
24.
go back to reference Shibeko AM, Lobanova ES, Panteleev MA, Ataullakhanov FI. Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa. BMC Syst Biol. 2010;4:5.CrossRefPubMedPubMedCentral Shibeko AM, Lobanova ES, Panteleev MA, Ataullakhanov FI. Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa. BMC Syst Biol. 2010;4:5.CrossRefPubMedPubMedCentral
Metadata
Title
Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants
Authors
Osamu Kumano
Shinya Suzuki
Masako Yamazaki
Yoshimori An
Masahiro Yasaka
Masahiro Ieko
For the Japanese Study Group for the Assessment of Direct Oral Anticoagulants
Publication date
09-02-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Hematology / Issue 4/2024
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-024-03712-4

Other articles of this Issue 4/2024

International Journal of Hematology 4/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine